CN1146782A - Enzymatic antimicrobial compositions - Google Patents
Enzymatic antimicrobial compositions Download PDFInfo
- Publication number
- CN1146782A CN1146782A CN95192407A CN95192407A CN1146782A CN 1146782 A CN1146782 A CN 1146782A CN 95192407 A CN95192407 A CN 95192407A CN 95192407 A CN95192407 A CN 95192407A CN 1146782 A CN1146782 A CN 1146782A
- Authority
- CN
- China
- Prior art keywords
- vanadium
- chloroperoxidase
- mould
- enzymatic
- hydrogen peroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 36
- 230000002255 enzymatic effect Effects 0.000 title claims description 37
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 95
- 108010035722 Chloride peroxidase Proteins 0.000 claims abstract description 63
- 102000003992 Peroxidases Human genes 0.000 claims description 58
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 58
- 229940088598 enzyme Drugs 0.000 claims description 53
- 102000004190 Enzymes Human genes 0.000 claims description 52
- 108090000790 Enzymes Proteins 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 38
- 108010016350 vanadium chloroperoxidase Proteins 0.000 claims description 32
- 244000005700 microbiome Species 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 17
- 239000004366 Glucose oxidase Substances 0.000 claims description 9
- 108010015776 Glucose oxidase Proteins 0.000 claims description 9
- 229940116332 glucose oxidase Drugs 0.000 claims description 9
- 235000019420 glucose oxidase Nutrition 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 108020005091 Replication Origin Proteins 0.000 claims description 3
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 230000037029 cross reaction Effects 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 101710143559 Vanadium-dependent bromoperoxidase Proteins 0.000 abstract description 3
- 150000004820 halides Chemical class 0.000 abstract description 2
- 241001537312 Curvularia inaequalis Species 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 143
- 239000000243 solution Substances 0.000 description 75
- 239000000725 suspension Substances 0.000 description 37
- 239000007979 citrate buffer Substances 0.000 description 36
- 230000001665 lethal effect Effects 0.000 description 35
- 230000001580 bacterial effect Effects 0.000 description 32
- 231100000518 lethal Toxicity 0.000 description 31
- 241000894006 Bacteria Species 0.000 description 29
- 239000000523 sample Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000007788 liquid Substances 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 26
- 125000005843 halogen group Chemical group 0.000 description 24
- 239000012530 fluid Substances 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000013016 damping Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 238000003860 storage Methods 0.000 description 17
- 238000005406 washing Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- -1 thiocyanic acid ion Chemical class 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229910052720 vanadium Inorganic materials 0.000 description 12
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 229920001817 Agar Polymers 0.000 description 10
- 241001136616 Methone Species 0.000 description 10
- 239000008272 agar Substances 0.000 description 10
- 108010079058 casein hydrolysate Proteins 0.000 description 10
- 230000003021 clonogenic effect Effects 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- 241000557265 Drechslera biseptata Species 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 239000003599 detergent Substances 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 230000004899 motility Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- 241000194031 Enterococcus faecium Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- RVPMRNSNYCGGLE-UHFFFAOYSA-N bromidodioxygen(.) Chemical compound [O]OBr RVPMRNSNYCGGLE-UHFFFAOYSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000009631 Broth culture Methods 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- FYMBCBXJSPPHJQ-UHFFFAOYSA-N [Br].[V] Chemical compound [Br].[V] FYMBCBXJSPPHJQ-UHFFFAOYSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000009629 microbiological culture Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 5
- 241000266330 Alternaria chartarum Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000218746 Curvularia subpapendorfii Species 0.000 description 4
- 241001465183 Drechslera Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 102100038609 Lactoperoxidase Human genes 0.000 description 4
- 102000003896 Myeloperoxidases Human genes 0.000 description 4
- 108090000235 Myeloperoxidases Proteins 0.000 description 4
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 4
- 239000003945 anionic surfactant Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108010023244 Lactoperoxidase Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 101100112520 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CCA1 gene Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 230000002498 deadly effect Effects 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229940057428 lactoperoxidase Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000266326 Alternaria botrytis Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 241001236089 Curvularia nicotiae Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101150094690 GAL1 gene Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241001103617 Pseudomonas aeruginosa ATCC 15442 Species 0.000 description 2
- 241000589540 Pseudomonas fluorescens Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 240000006474 Theobroma bicolor Species 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 2
- NRFTYDWKWGJLAR-MELADBBJSA-N Tyr-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O NRFTYDWKWGJLAR-MELADBBJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- MZSDGDXXBZSFTG-UHFFFAOYSA-M sodium;benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1 MZSDGDXXBZSFTG-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- MZOLIRUJMQEVFZ-BYGOBXPBSA-N (1S,2S,3R,4S,5S)-1-(hydroxymethyl)-5-[6-(2-nitro-4-pyrimidin-2-ylanilino)hexylamino]cyclohexane-1,2,3,4-tetrol Chemical compound [O-][N+](C(C=C(C=C1)C2=NC=CC=N2)=C1NCCCCCCN[C@@H](C[C@](CO)([C@H]([C@@H]1O)O)O)[C@@H]1O)=O MZOLIRUJMQEVFZ-BYGOBXPBSA-N 0.000 description 1
- NJZHEQOUHLZCOX-ZENOOKHLSA-N (3aR,4R,9bS)-golgicide A Chemical compound C1([C@@H]2NC3=C(F)C=C(C=C3[C@H]3C=CC[C@H]32)F)=CC=CN=C1 NJZHEQOUHLZCOX-ZENOOKHLSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100322085 Arabidopsis thaliana CAC3 gene Proteins 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108010073997 Bromide peroxidase Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101001099464 Homo sapiens Lactoperoxidase Proteins 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- HRJXMHAOFRMRCR-UHFFFAOYSA-K O.[Na+].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+] Chemical compound O.[Na+].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+] HRJXMHAOFRMRCR-UHFFFAOYSA-K 0.000 description 1
- 101710157860 Oxydoreductase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101100514477 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MSI1 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000266300 Ulocladium Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical class N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 150000001804 chlorine Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001362 electron spin resonance spectrum Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- FPVGTPBMTFTMRT-NSKUCRDLSA-L fast yellow Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-NSKUCRDLSA-L 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XEMZLVDIUVCKGL-UHFFFAOYSA-N hydrogen peroxide;sulfuric acid Chemical compound OO.OS(O)(=O)=O XEMZLVDIUVCKGL-UHFFFAOYSA-N 0.000 description 1
- MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004028 organic sulfates Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 208000033610 salivary peroxidase Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- MWNQXXOSWHCCOZ-UHFFFAOYSA-L sodium;oxido carbonate Chemical compound [Na+].[O-]OC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-L 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- WQEVDHBJGNOKKO-UHFFFAOYSA-K vanadic acid Chemical compound O[V](O)(O)=O WQEVDHBJGNOKKO-UHFFFAOYSA-K 0.000 description 1
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/16—Antifouling paints; Underwater paints
- C09D5/1606—Antifouling paints; Underwater paints characterised by the anti-fouling agent
- C09D5/1612—Non-macromolecular compounds
- C09D5/1625—Non-macromolecular compounds organic
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38654—Preparations containing enzymes, e.g. protease or amylase containing oxidase or reductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An antimicrobial composition is provided, comprising a Vanadium haloperoxidase, a source of halide and hydrogen peroxide or a source of hydrogen peroxide. Preferably, the Vanadium haloperoxidase is a chloroperoxidase obtainable from Curvularia inaequalis.
Description
Technical field
The present invention relates to enzymatic antimicrobial composition and application thereof.More particularly, relate to and contain vanadium-halogenated peroxidase (Vanadium haloperoxidase), the enzymatic antimicrobial composition of hydrogen peroxide cource and halide source.The invention still further relates to and adopt recombinant DNA technology to produce the vanadium-halogenated peroxidase, this salt can be used in the enzymatic antimicrobial composition.
The prior art background
Various enzymatic antimicrobial composition are known in the art.For example, WO-A-94/04217 discloses stable dentifrice composition, and said composition can produce the low thiocyanic acid ion (OSCN of antimicrobial effective concentration
-).Said composition contains the oxydo-reductase that produces hydrogen peroxide and thiocyanate ion can be oxidized to antimicrobial low thiocyanic acid ion (OSCN
-) peroxidase, said thiocyanate ion is present in the saliva usually.Suitable peroxidase comprises lactoperoxidase, myeloperoxidase, salivary peroxidase and chloroperoxidase.
The enzymatic antimicrobial composition that contains the halo peroxidase is also disclosed at EP-A-500387 (Exoxemis).The document has been described at halo peroxidase in the presence of superoxide and the halogenide and optionally has been attached on the target microorganism and suppresses its growth.The suitable halo peroxidase that EP-A-500387 introduces is myeloperoxidase (MEP), eosinophilic granulocyte (EPO), lactoperoxidase (LPO), and chloroperoxidase (CPO).Reported that the ratio of halogenide and hydrogen peroxide is a key factor with regard to the stability of halo peroxidase and function.When low-down ratio, hydrogen peroxide can suppress the function of halo peroxidase, and when very high ratio, halogenide can hinder enzymatic reaction.This ratio can change in a wide region, but preferably is maintained at about more than 50.
Owing to there is the undesirable side reaction of hydrogen peroxide, concentration of hydrogen peroxide actual in this antimicrobial composition is lower than what expect.Therefore, the halogenide of the hydrogen peroxide of inventor's discovery high initial concentration of use in this antimicrobial composition and convention amount may be more satisfactory.
Moreover, need the anti-microbial activity of a kind of and known enzymatic antimicrobial composition to compose different enzymatic antimicrobial composition.Preferably, said composition should have and resists for example anti-microbial activity of streptococcus faecium of the microorganism be difficult to resist.Under other environment, it also is desired can also resisting non-pathogenic microorganism, because these microorganisms can cause the corruption of food.
Therefore the purpose of this invention is to provide a kind of enzymatic antimicrobial composition, said composition has overcome top said one or more shortcomings.
We are surprised to find and use the vanadium-halogenated peroxidase can prepare especially effectively enzymatic antimicrobial composition now.
The prior art of introducing above comprises the various halo peroxidase that is used for antimicrobial composition, but does not pay particular attention to the vanadium-halogenated peroxide enzyme up to now.
The vanadium-halogenated peroxide enzyme is different from other halo peroxidase, and difference is that the prothetic group of these enzymes has the constitutional features that is similar to vanadate (vanadium V), and other halo peroxidase is the protoheme peroxidase.
Further purpose of the present invention is that its sequence is cloned and measured to the gene of a kind of vanadium-halogenated peroxidase of coding so that it is expressed in the microorganism that other is convenient to grow, and utilizes recombinant DNA technology to improve the output of this enzyme.
Some vanadium bromine peroxide enzymes (Wever et al., 1991) have been found on the surface of natural seaweed.The vanadium bromine peroxide enzyme is easy to be subjected to the influence of substance and can discharges HOBr by adding hydrogen peroxide in the whole plant in seawater.Still do not establish the effect of this enzyme, but the HOBr that forms the hyperoxia voltinism in seawater may be a part that hinders the system of defense that microorganism or fungi grow in its surface as plant.
After from tubercle capsule leaf algae, finding non-heme vanadium bromine peroxide enzyme, proved that a large amount of marine alga kinds also contains these enzymes.Particularly, the bromine peroxide enzyme of finding extensive studies and qualitative (as comment, document sees reference) have been carried out from tubercle capsule leaf algae.The prothetic group of these enzymes has the constitutional features that is similar to vanadate (vanadium V).The catalytic mechanism of these enzymes is: peroxidase and this enzyme react to form hydrogen peroxide-enzyme complex, and a bromide and a proton and this mixture react to form an enzyme-HOBr mixture afterwards.Verified (De Boer et al., 1988) this mixture decay forms enzyme and HOBr.Prove that also these vanadium bromine peroxide enzymes (De Boer et al., 1988) have operational high stability in water and organic medium.For example, these enzymes are stable and at organic solvent acetone for example, methyl alcohol can store the time more than one month in ethanol (content is up to 60%) and the 1-propyl alcohol in three weeks under the turnover condition, and loss of activity not.But these enzymes have disadvantageous one side, and the existence or the adding of bromide promptly must be arranged when practical application, and the gene clone of the bromine peroxide enzyme of coding marine alga and the trial of measuring its aminoacid sequence are not achieved success.
Because its genetic instability and its low optimal pH are 2.75 (J.R.Kanofsky, 1984) (these characteristics have seriously limited it and used) existing known chloroperoxidase that contains protoheme from dark brown Ka Erhei enzyme is suitable for preparing the enzymatic antimicrobial composition hardly, similar arguement has hindered the application from the myeloperoxidase of people's white cell (MPO), this enzyme also can produce HOCl (A.R.J.Bakkenist et al., 1980).
Also the someone reports the halo peroxidase that ( document 8,9 sees reference) dark-coloured spore thread fungus secretion has obvious stability.Proved that particularly the Lu Sheng fungi do not wait a kind of vanadium chloroperoxidase of the mould secretion of curved spore people such as (, 1993) J.W.P.M.Van Schijndel, this enzyme and muriate have high-affinity and have optimal pH 5.5 when participating in chlorination reaction.When the bromine peroxide enzyme that is used to from marine alga, the prothetic group of chloroperoxidase has the structural performance that is similar to vanadate (vanadium V).More studying in great detail in (people such as J.W.P.M.Van Schijndel, 1993) subsequently, be similar to vanadium bromine peroxide enzyme from tubercle capsule leaf algae by the muriatic enzyme kinetics of hydrogen peroxide oxidation.In addition, three kinds of diverse ways show that this enzyme produces a kind of reaction product oxidized chlorine class (HOCl) and this product itself is had resistance.This enzyme shows high heat stability (Tm90 ℃) and at organic solvent 40% methyl alcohol for example, has the stability of height in ethanol and the propyl alcohol.
Summary of the invention
First aspect the present invention relates to a kind of enzymatic antimicrobial composition, and it contains the vanadium-halogenated peroxidase, halogenide and hydrogen peroxide cource or hydrogen peroxide cource.
According to second aspect, the present invention relates to the production of vanadium-halogenated peroxidase, comprise that transforming appropriate host by means of a kind of expression vector (contains a replication origin in the carrier, transcribe and stop control sequence and to the dna sequence dna of small part coding vanadium-halogenated peroxidase), under the condition that allows expression of structural gene, cultivate this host and separate the vanadium-halogenated peroxidase.
Detailed Description Of The Invention
(a) vanadium-halogenated peroxidase
Enzymatic antimicrobial composition of the present invention contains the vanadium-halogenated peroxidase as first composition.This vanadium peroxidase is selected from disclosed in the prior art various vanadium-halogenated peroxidase in principle.For example can use the vanadium-halogenated peroxidase (non-heme) that never waits the mould generation of curved spore, describe as US-A-4707466.Another kind of available method is that the description according to people (1993) such as J.W.P.M.Van Schijndel never waits isolated or purified chloroperoxidase in the curved spore mould (CBS102.42).
The source of other vanadium-halogenated peroxidase comprises Drechslera biseptata (CBS 371.72), Drechslera fuqax (CBS 509.77), Drechslera nicotiae (CBS 655.74), Drechslera subpapendorfii (656.74), Embelisia hyacinthi (416.71), Embelisia didymospora (CBS 766), Ulocladium chartarum (200.67) and Ulocladium botrytis (452.72).
Another kind of available method, can adopt recombinant DNA technology to prepare the vanadium-halogenated peroxidase, comprise by means of a kind of expression vector and transform appropriate host, said carrier contains a kind of replication origin, transcribe or stop the dna sequence dna of control sequence and coding vanadium-halogenated peroxidase, under the condition that allows expression of structural gene, cultivate this host and separate the vanadium-halogenated peroxidase.To be described in detail among the embodiment hereinafter.
(b) source of halide ions
Second moiety of health composition of the present invention is a source of halide ions.They can be any source of halide ions, but iodide or chloride ion are preferred, because they are the most effective.Sodium-chlor is the most effective source of halide ions.This halogenide can be added in the enzymatic antimicrobial composition of the present invention, the perhaps available natural halogenide that is present in the tap water replaces, and its consumption is generally 2-5mM.
(c) hydrogen peroxide cource
Health composition of the present invention further comprises hydrogen peroxide cource or produces the system of hydrogen peroxide.The system of suitable generation hydrogen peroxide is peroxyboric acid or percarbonate, preferably SPC-D or Sodium peroxoborate.
Also can provide hydrogen peroxide by enzymatic peroxidation hydrogen generation system.Enzymatic peroxidation hydrogen generation system can be selected from the antibiotic superoxide of disclosed in the prior art various enzymatics and produce system in principle.For example, can use amine oxidase and amine, amino-acid oxidase and amino acid, Lactate Oxidase and lactic acid, rCO and cholesterol, urico-oxidase and uric acid or XOD and xanthine, preferably, the combination of glucose oxidase and glucose.
The amount of glucose oxidase will depend on that it is than any residual Peroxidase activity of living and may exist, in general every milliliter of detergent compositions of the present invention or every gram contain 10-1000, the glucose oxidase of 20-500 unit preferably, the definition of per unit enzymic activity is the required amount of substrate that per minute transforms 1 μ mol under standard state.
(d) other composition
It is 0.01-50% that enzymatic antimicrobial composition of the present invention contains weight percent usually, and preferably one or more tensio-active agents of 0.1-5.0% are as moistening agent.Suitable tensio-active agent or stain remover active compound are soap or non-soap anionic, nonionic, positively charged ion, both sexes or zwitterionic compound.Surfactant system contains a kind of and multiple anion surfactant and one or more nonionogenic tensides usually.This surfactant system also contains both sexes or zwitterionic detergent compound in addition, but because its expense is higher relatively, usually can not be satisfactory.
In general, the nonionic of this surfactant system and anion surfactant can be selected from by Schwartz﹠amp; Perry, Interscience 1949, Vol.1 " tensio-active agent " and by Schwartz, Perry ﹠amp; Berch, Interscience 1958, Vol.2, " McCutcheon ' sEmulsifiers and Detergents " current version or " Tenside-Taschenbuch " that publishes by Manufacturing Confectioners Company, H.Stache, second edition., Carl Hauser Verlag, 1981 tensio-active agents of describing.
Operable suitable nonionic detergent compound is particularly including the fatty alcohol for example of the compound with a hydrophobic grouping and a hydrogen atoms, acid, acid amides or alkylphenol and alkene oxide, the reaction product of the oxyethane of especially independent oxyethane or coupling collar Ethylene Oxide.Specific nonionic detergent compound is C
6-C
22Alkylphenol-ethylene oxide condensate (per molecule contains 5-25EO usually, i.e. the oxyethane of 5-25 unit) and aliphatic C
8-C
18The reaction product of one-level or secondary linearity or branched-chain alcoho and oxyethane, 5-40 EO usually.
Operable suitable anionic detersive immunomodulator compounds is the water-soluble alkali metal salts of organo-sulfate and sulphonate normally, and it contains the alkyl of 8-22 the carbon atom of having an appointment, and employed term alkyl comprises the moieties of senior acyl group.The example of suitable synthetic anionic stain remover compound is that sodium alkyl sulfate and potassium are (especially by making high-grade C
8-C
18The alcohol sulfation produces from for example fatty oil or theobroma oil), alkyl C
9-C
20Benzene sulfonic acid sodium salt and potassium, particularly linear secondary alkyl C
10-C
15Benzene sulfonic acid sodium salt and alkyl glycerol ether sodium sulfate are especially from the ether of fatty oil or theobroma oil deutero-higher alcohols with from the ether of the synthol of petroleum derivation.Preferred anionic surfactants stain remover compound is C
11-C
15Sodium alkyl benzene sulfonate and C
12-C
18Sodium alkyl sulfate.
Also can use those tensio-active agents (these tensio-active agents show the resistance of having saltoutd) of in EP-A-328177 (Unilever), describing, alkyl poly glucoside tensio-active agent of in EP-A-070074, describing and alkyl list glucoside.
The preferred surfactants system is the mixture of negatively charged ion and nonionic detergent active substance, particularly negatively charged ion and nonionogenic tenside group and the example of pointing out at EP-A-346995 (Unilever).Especially preferred is C
16-C
18Monohydroxy-alcohol sulfuric acid an alkali metal salt and 3-7 EO ethoxylation C
12-C
15The surfactant system of monohydroxy-alcohol mixture.
Preferably this nonionic detergent in surfactant system shared weight greater than 10%, 25-90% for example.For example anion surfactant shared weight in surfactant system is in the scope of about 5%-40%.
Enzymatic detergent compositions of the present invention can also comprise other composition that is generally used in the antimicrobial composition, for example thickening material.Relevant this point particularly suitable be combination at the disclosed tensio-active agent of EP-A-314232 (Unilever), the document provides the thickening gel in the water soluble.
Antimicrobial composition of the present invention can be used for cleaning rigid surface and laundering of textile fabrics, but also can be used for industry or research institution for example hospital health and cleaning and be used for the cleaning and disinfection medical facilities.Other application is at the industrial sterilization system milk equipment that is used for of system milk.Cause the ability of malodorous bacterium because it has to resist, this antimicrobial composition also can be successfully used to deodorizing.
Antimicrobial composition of the present invention can use to need powder type soluble in water before using, but also can be mixed with liquid product or gel.The generation that can not start hypohalite in those product forms before said composition is used is important.By enzyme and its substrate are separated, for example by adopting known technology that the enzyme bag is got up to accomplish this point.
When using antibiotic enzymatic composition, by thin up 5-100 doubly so that preparation has the medium of imitating anti-microbial activity.Then it is contacted with the surface that is allowed to use with to be sterilized.Reference
1.R.Wever, the bromination activity of M.G.M.Tromp.B.E.Krenn A.Marjani and M.van Tol. tubercle capsule leaf algae: to the influence in biosphere.Envir.Sc.Techn.25(1991),446-449.
2.R.Wever and K.Kustin. vanadium: a kind of biological coherent element.Adv.Inorg.Chem.35(1990),81-115.
3.D.Rehder. the bio-inorganic chemistry of vanadium.Ang.Chem.Ed.Engl.30(1991)148-167.
4.E.de the reaction mechanism of the vanadium bromine peroxide enzyme that Boer and R.Wever. are new, a kind of stability kinetics analysis.J.Biol.Chem.263(1988),12326-12332.
5.E.de Boer, H.Plat, M.G.M.Tromp, M.C.R.Franssen, H.C.van derPlas, E.M.Meijer and H.E.Schoemaker. contain the bromine peroxide enzyme of vanadium: the example at the stable oxydo-reductase of water and organic medium camber.BiotechnBioeng.30(1987),607-610.
6.J.R.Kanofsky. singlet oxygen by chloroperoxidase-hydrogen peroxide-halide system generation.J.Biol.Chem.259(1984),5596-5600.
7.A.R.J.Bakkenist, J.E.G.de Boer, the halogenide mixture of H.Plat and R.Wever. chloroperoxidase and halogenating reaction mechanism.Biochim.Biophys.Acta613(1980),337-348.
8.J.C.Hunter-Cevera and L.Sotos. screens " newly " enzyme at occurring in nature: prepare the halo peroxidase with Death Valley dematiaceous hyphomycetes.Microb.Ecol.12(1986)121-127.
9.T-N.E.Liu, T.MTimkulu, J.Geigert, B.Wolf, S.L.Neidleman, the separating and sign of the non-heme chloroperoxidase that D.Silva and J.C.Hunter-Cevera. are new.Biochem.Biophys.Res.Commun.142(1987),329-333.
10.J.W.P.M.Van Schijndel, E.G.M.Vollenbroek and R.Wever. are from not waiting mould chloroperoxidase of curved spore; A kind of new vanadium enzyme.Biochim.Biophys.Acta.1161(1993),249-256.
11.Van Schijndel, J.W.P.M., Barnett, P., Roelse, J., Vollenbroek, E.G.M. and Wever, R. is from not waiting mould vanadium chloroperoxidase of curved spore; Stability and stability kinetics (1994) Eur.J.Biochim.225,151-157.
12.H.Schagger with G.Von Jagow (1987) Anal.Biochem.166,368-379.
13.P.Matsudaira(1987)J.Biol.Chem.262,10035-10038.
14.Sambrook,J.,Fritch,E.F.and?Maniatis,T.(1989)Molecular?Cloning:a?Laboratory?Manual,2nd?edn.,Cold?Spring?Harbor?Laboratory,ColdSpring?Harbor,NY.
15.R.Wever,H.Plat?and?E.de?Boer(1985),Biochem.Biophys.Acta830,181-186.
Can further set forth the present invention by means of following non-limiting example.
The minimum inhibitory concentration of hypochlorite (MIC)
Material:
The bacterial isolates of Shi Yonging is intestinal bacteria NCTC900 in the present embodiment, Pseudomonas aeruginosa ATCC15442, streptococcus aureus ATCC13565, streptococcus faecium NCTC1092 and harmless Li Site bacterium ATCC33090 serotype 6B.Soak in juice (BHI) broth culture at the brain heart, 30 ℃ with after microbial culture 15-18 hour, with bacterial strain washed twice in pH5.5 citrate buffer solution (20mM trisodium citrate-NaOH damping fluid+10mM NaCl).With bacterial suspension centrifugal on the Eppendorf whizzer (14000rpm, 5 minutes), remove supernatant liquor then and bacterial precipitation is suspended in the citrate buffer solution.Various bacterial suspensions are repeated this washing step once.Then with the pH5.5 citrate buffer solution dilute this through the bacterial suspension of twice washing to obtain every milliliter about 10
7The suspension of bacterium.Carry out in the process at washing step, cell remains in the ice bath.With damping fluid and BSA solution (1%w/v is dissolved in the pH5.5 citrate buffer solution) filtration sterilization and be stored in 4 ℃.By with the dilution of aseptic deionized water from storage liquid (107,000ppm) preparation hypochlorite solutions.
Method:
Utilize aseptic technique, preparation is dissolved in every milliliter about 10 in the pH5.5 citrate buffer solution
7The suspension of bacterium.Getting this suspension 1.9ml joins in the sterile test tube.0.1ml the cold hypochlorite solutions of various concentration is added in these test tubes, to obtain various dilution hypochlorites.Use a bar magnet agitator respectively with these test tube mixings then.Blank determination is to use sterile buffer to substitute hypochlorite solutions.At 30 ℃ sample accurately is incubated 5 minutes.Get the 1ml reaction mixture then, join in the cold BSA of 9ml (1%w/v) solution and place ice bath immediately, to stop the reaction of hypochlorite and microorganism.With sample from 10
-1Be diluted to 10
-5And 100 μ l samples of each diluent are placed on the BHI agar plate of mark and cultivate, be expressed as motility rate with the clonogenic unit (CFU) in every milliliter.30 ℃ flat board cultivated 15-18 hour after, if do not detect CFU, then flat board was cultivated 24 hours again at 30 ℃.
Definition: minimum inhibitory concentration (MIC value) is defined as the concentration that the clonogenic unit that causes the specified microorganisms that detected under employed experiment condition reduces the required hypochlorite of six orders of magnitude at least herein.
The results are shown in table 1.The scope of numerical value wherein is identical with bibliographical information.
The MIC value of the various microorganisms of table 1.
Microorganism | The MIC value is represented with ppm |
Intestinal bacteria | ????????2-3 |
Streptococcus aureus | ????????2-3 |
Harmless Li Site bacterium | ????????2-3 |
Pseudomonas fluorescens | ????????2-3 |
Streptococcus faecium | ????????2-3 |
The minimum inhibitory concentration of hypochlorite and by from the hypochlorite that does not wait mould vanadium chloroperoxidase (V-CPO) enzymatic of curved spore to produce
In the present embodiment, compare with the lethal effect of hypochlorite and by lethal effect from the hypochlorite that does not wait mould vanadium chloroperoxidase (V-CPO) enzymatic of curved spore to produce.In order to compare, used a Micropump.This step can be according to being similar to the Experiment Preparation hypochlorite concentration that enzymatic produces hypochlorite.Under this experiment condition, also very carefully determine the V-CPO activity, thereby can know the amount of the hypochlorite that exists at each time point of testing.
Material:
The bacterial isolates of Shi Yonging is intestinal bacteria NCTC900 in the present embodiment, Pseudomonas aeruginosa ATCC15442, streptococcus aureus ATCC13565, streptococcus faecium NCTC1092 and harmless Li Site bacterium ATCC33090 serotype 6B.Soak in juice (BHI) broth culture at the brain heart, 30 ℃ with microbial culture 15-18 hour.After cultivating, with bacterial strain washed twice in pH5.5 citrate buffer solution (20mM trisodium citrate-NaOH damping fluid+10mM NaCl).With bacterial suspension centrifugal on the Eppendorf whizzer (14000rpm, 5 minutes), remove supernatant liquor then and subsequently bacterial precipitation is suspended in the citrate buffer solution.Repeat this washing step once for various bacterial suspensions then.Then with the pH5.5 citrate buffer solution dilute this through the bacterial suspension of twice washing to obtain every milliliter about 10
7The suspension of bacterium.Carry out in the process at washing step, cell remains in the ice bath.With damping fluid and BSA solution (1%w/v is dissolved in the pH5.5 citrate buffer solution) filtration sterilization and be stored in 4 ℃.By with the dilution of aseptic deionized water from storage liquid (107,000ppm) preparation hypochlorite solutions.By preparing superoxol from 30% storage liquid with the aseptic deionized water dilution.Casein hydrolysate obtains from Difco.According to people such as Van Schijndel, the method for (1993) never waits the mould purifying chloroperoxidase of curved spore.30 ℃ at 20mM pH5.5 sodium citrate buffer solution, 10mM sodium-chlor, 100 μ M hydrogen peroxide, in 50 μ M, the one chlorine methone by with a chlorine methone (e290nm=20.2mM
-1.cm
-1) be converted into dichloro methone (e 290nm=0.2mM
-1.cm
-1) determine that with spectrophotometer chloroperoxidase is with Cl afterwards
-Be converted into the activity among the HOCl.The definition of the chloroperoxidase of a unit is the required enzyme amount of a chlorine methone (Sigma) that transforms 1 μ mol at per minute.
Method:
Utilize aseptic technique, preparation is dissolved in every milliliter about 10 in the pH5.5 citrate buffer solution
7The suspension of bacterium.Get the 1.8ml sample from this suspension and join the aseptic reaction vessel, stir continuously with the bar magnet agitator at whole experimental session.The cold V-CPO solution of the various concentration of 0.2ml is added in these containers subsequently, to obtain different dilution V-CPO solution (its method of calculation see below).Blank determination is to substitute 0.2mlV-CPO solution with adding the 0.2ml sterile buffer.At 30 ℃ reaction vessel is incubated.The hydrogen peroxide storage liquid that adds 0.5ml then is so that start the V-CPO reaction.The concentration of employed hydrogen peroxide storage liquid decide according to the hypochlorite concentration that is produced, and is that the mode of five times of molar excess is selected according to the final concentration of comparing hydrogen peroxide with the final concentration of hypochlorite (when flowing end).At 30 ℃ sample accurately is incubated 5 minutes.Get the 1ml reaction mixture then, join in the cold BSA of 9ml (1%w/v) solution and place ice bath immediately, to stop the reaction of hypochlorite and microorganism.With sample from 10
-1Be diluted to 10
-5And 100 μ l samples of each diluent are placed on the BHI agar plate of mark and cultivate, (CFU) is expressed as motility rate with every milliliter clonogenic unit.At 30 ℃ flat board was cultivated 15-18 hour then.If do not detect CFU, then flat board was cultivated 24 hours again at 30 ℃.
MIC value that is obtained and the MIC value that the hypochlorite that uses a Micropump to add same amount obtains are compared.This step is finished as follows:
Utilize aseptic technique, preparation is dissolved in every milliliter about 10 in the pH5.5 citrate buffer solution
7The suspension of bacterium.Get the 1.8ml sample from this suspension and join the aseptic reaction vessel, stir continuously with the bar magnet agitator at whole experimental session.At 30 ℃ reaction vessel is incubated.The hydrogen peroxide storage liquid that adds 0.2ml then, the concentration of employed hydrogen peroxide storage liquid decide according to the hypochlorite concentration that is produced, and is that the mode of five times of molar excess is selected according to the final concentration of comparing hydrogen peroxide with the final concentration of hypochlorite (when flowing end).In 30 ℃ of times of 5 minutes, the hypochlorite solutions 0.5ml effluent (flow velocity 0.1ml/ minute) of concentration known is gone up sample then.Utilize the various hypochlorite solutions of different concns to finish a series of experiment respectively, so that obtain a series of hypochlorite final concentration (its calculating sees below).After being incubated 5 minutes, get the 1ml reaction mixture, join the cold BSA of 9ml (1%w/v) solution and place ice bath immediately, to stop the reaction of hypochlorite and microorganism.With sample from 10
-1Be diluted to 10
-5And 100 μ l samples of each diluent are placed on the BHI agar plate of mark and cultivate, be expressed as motility rate with the clonogenic unit (CFU) in every milliliter.At 30 ℃ flat board was cultivated 15-18 hour then.If do not detect CFU, then flat board was cultivated 24 hours again at 30 ℃.
Use same experiment setting (with regard to blank assay, not adding microorganism), and spectrophotometer, by with a chlorine methone (e 290nm=20.2mM
-1.cm
-1) be converted into dichloro methone (e 290nm=0.2mM
-1.cm
-1), measure hypochlorite concentration at the 290nm place and the similar hypochlorite of storing liquid that comes from of hypochlorite that obtains with V-CPO respectively that confirms to describe hereinbefore on time.
Calculate:
The final concentration of the hypochlorite that produces with V-CPO calculates as follows:
With the V-CPO of every milliliter of 0.01U, every milliliter of hypochlorite that produces 0.01 μ mol in per minute is equivalent to the hypochlorite that every ml in per 5 minutes produces 0.05 μ mol.Because the dilution effect (it joins in the initial volume of 2.0ml) of 0.5ml effluent, the final concentration after 5 minutes produces 0.04 μ mol hypochlorite for every ml after (2.0/2.5) * 0.05 μ mol/ml=5 minute.Subsequently this concentration is expressed as 0.04 μ mol hypochlorite/ml=0.04 * 52.5ppm hypochlorite=2.10ppm hypochlorite.Obtain other hypochlorite final concentration by improving or reduce V-CPO concentration.The hypochlorite final concentration that is added calculates as follows: owing to added the 0.5ml effluent in the reaction volume of 2.0ml, final volume is 2.5ml, is equivalent to dilute 5 times.In order to obtain the hypochlorite final concentration of 2.10ppm, use 10.50ppm storage liquid.By improving or reduce the hypochlorite concentration that hypochlorite storage liquid obtains other.
Definition: minimum inhibitory concentration (MIC value) is defined as the concentration that the clonogenic unit that causes the specified microorganisms that detected under employed experiment condition reduces the required hypochlorite of six orders of magnitude at least herein.
The results are shown in the Table II.Various final concentrations that will be produced by V-CPO or the hypochlorite when hypochlorite flows out end compare.From Table II as can be seen, the hypochlorite that is produced by the V-CPO enzymatic has the growth-inhibiting effect to all organisms except that streptococcus aureus when hypochlorite concentration is low to moderate 0.4ppm, need the 2ppm hypochlorite and obtain same growth inhibitory effect.The halo peroxidase that this demonstration contains vanadium is than the more effective health composition of its hypochlorite.Obviously V-CPO also has and kills that all that detected are caused a disease and abilities of non-pathogenic microorganism, and it is said that the halo peroxidase that contains protoheme only has the effectiveness (referring to EP-A-500387) of killing malignant bacteria.
The MIC value of the various microorganisms of Table II
Microorganism | MIC value (ppm) with hypochlorite | MIC value (ppm) with V-CPO |
Intestinal bacteria | ????????2 | ??????0.4 |
Streptococcus aureus | ???????2-3 | ??????1.6 |
Harmless Li Site bacterium | ????????2 | ??????0.4 |
Pseudomonas fluorescens | ????????2 | ??????0.4 |
Streptococcus faecium | ????????2 | ??????0.4 |
The deadly effectiveness of hypochlorite and the hypochlorite that in the presence of protein hydrolystate, produces by the V-CPO enzymatic
In order to reach the purpose of health, known to actual situation of running into, it is necessary using excessive hypochlorite, because this reactive behavior molecule not only reacts with microorganism, and reacts with other compound that exists.Therefore the behavior that detects the halo peroxidase that contains vanadium in containing the fluid of protein hydrolystate for example is important.
Material:
The bacterial isolates of Shi Yonging is intestinal bacteria NCTC900 in the present embodiment.Soak in juice (BHI) broth culture at the brain heart, 30 ℃ with microbial culture 15-18 hour.After cultivating, with bacterial strain washed twice in pH5.5 citrate buffer solution (20mM trisodium citrate-NaOH damping fluid+10mM NaCl).With bacterial suspension centrifugal on the Eppendorf whizzer (14000rpm, 5 minutes), remove supernatant liquor then and subsequently bacterial precipitation is suspended in the citrate buffer solution.Repeat this washing step once for various bacterial suspensions then.Then with the pH5.5 citrate buffer solution dilute this through the bacterial suspension of twice washing to obtain the suspension of every milliliter of about 108 bacteriums.Carry out in the process at washing step, cell remains on ice.With damping fluid and BSA solution (1%w/v is dissolved in the pH5.5 citrate buffer solution) filtration sterilization and be stored in 4 ℃.By with the dilution of aseptic deionized water from storage liquid (107,000ppm) preparation hypochlorite solutions.By preparing superoxol from 30% storage liquid with the aseptic deionized water dilution.Casein hydrolysate obtains from Difco.Method according to people (1993) such as Van Schijndel never waits the mould purifying chloroperoxidase of curved spore.
Method:
Utilize aseptic technique, preparation is dissolved in every milliliter about 10 in the pH5.5 citrate buffer solution
8The suspension of bacterium.Getting the 1.3ml sample from this suspension joins the aseptic reaction vessel, stir continuously with the bar magnet agitator at whole experimental session, 0.5mg/ml casein hydrolysate (the being dissolved in the pH5.5 citrate buffer solution) solution that adds 0.5ml subsequently respectively, 0.5ml pH5.5 citrate buffer solution solution, cold each 0.2ml of V-CPO solution (its method of calculation see below) that in these containers, adds various concentration in the mode of the concentration that obtains 3.2ppm or 6.5ppm hypochlorite.Blank determination is only to add the sterile buffer of 0.2ml to substitute the V-CPO solution of 0.2ml.At 30 ℃ reaction vessel is incubated.The superoxol that adds 0.5ml then is so that start the V-CPO reaction.The selection of the concentration of superoxol is according to the hydrogen peroxide that obtains five times of molar excess when flowing end.At 30 ℃ sample accurately is incubated 5 minutes.Get the 1ml reaction mixture after cultivating, join the cold BSA of 9ml (1%w/v) solution and place ice bath immediately, to stop the reaction of hypochlorite and microorganism.With sample from 10
-1Be diluted to 10
-5And 100 μ l samples of each diluent are placed on the BHI agar plate of mark and cultivate, be expressed as motility rate with the clonogenic unit (CFU) in every milliliter.At 30 ℃ flat board was cultivated 15-18 hour then.If do not detect CFU, then flat board was cultivated 24 hours again at 30 ℃.
Lethal effect that is obtained and the lethal effect that the hypochlorite that uses a Micropump to add same amount obtains are compared.This step is finished as follows:
Utilize aseptic technique, preparation is dissolved in every milliliter about 10 in the pH5.5 citrate buffer solution
8The suspension of bacterium.Getting the 1.3ml sample from this suspension joins the aseptic reaction vessel, stir continuously with the bar magnet agitator at whole experimental session, 0.5mg/ml casein hydrolysate (the being dissolved in the pH5.5 citrate buffer solution) solution that adds 0.5ml subsequently respectively, the pH5.5 citrate buffer solution solution of 0.5ml.The aseptic pH5.5 citrate buffer solution that adds 0.2ml then.Reaction vessel is 30 ℃ of insulations.Then in 30 ℃ of times of 5 minutes with sample on the effluent of the hypochlorite solutions of 0.5ml, produce the hypochlorite final concentration (calculating of concentration is referring to embodiment 2) of 3.2ppm or 6.5ppm.Get the 1ml reaction mixture after the insulation, join the cold BSA of 9ml (1%w/v) solution and place ice bath immediately, to stop the reaction of hypochlorite and microorganism.With sample from 10
-1Be diluted to 10
-6And 100 μ l samples of each diluent are placed on the BHI agar plate of mark and cultivate, (CFU) is expressed as motility rate with every milliliter of clonogenic unit.At 30 ℃ flat board was cultivated 15-18 hour then.If do not detect CFU, then flat board was cultivated 24 hours again at 30 ℃.The results are shown in Table III.The Table III casein hydrolysate is to the influence of the deadly effectiveness of the HOCl that produced by V-CPO
The concentration of casein hydrolysate (mg/ml) | Use the log value of the 3.2ppm hypochlorite reduction that produces by V-CPO | Use the log value of the hypochlorite reduction that produces by 3.2ppm | Use the log value of the 6.Sppm hypochlorite reduction that produces by V-CPO | Use the log value of the hypochlorite reduction that produces by 6.5ppm |
?0.0 | (8.0=complete lethal) | (8.2=complete lethal) | (8.0=complete lethal) | (8.2=complete lethal) |
?0.1 | ??????5.0 | ?????0.5 | (8.0=complete lethal) | ?????1.0 |
The halo peroxidase and the deadly comparison of rendeing a service of the halo peroxidase that contains protoheme that contain vanadium
Material:
The bacterial isolates of Shi Yonging is intestinal bacteria NCTC900 in the present embodiment, streptococcus faecium NCTC1092 and harmless Li Site bacterium ATCC33090 serotype 6B.Soak in juice (BHI) broth culture at the brain heart, 30 ℃ with microbial culture 15-18 hour.After cultivating, with bacterial strain washed twice in pH5.5 citrate buffer solution (20mM trisodium citrate-NaOH damping fluid+10mM NaCl).With bacterial suspension centrifugal on the Eppendorf whizzer (14000rpm, 5 minutes), remove supernatant liquor then and subsequently bacterial precipitation is suspended in the citrate buffer solution.Repeat this washing step once for various bacterial suspensions then.Then with the pH5.5 citrate buffer solution dilute this through the bacterial suspension of twice washing to obtain every milliliter about 10
7The suspension of bacterium.Carry out in the process at washing step, cell remains in the ice bath.With damping fluid and BSA solution (1%w/v is dissolved in the pH5.5 citrate buffer solution) filtration sterilization and be stored in 4 ℃.Method according to people (1993) such as Van Schijndel never waits the mould purifying chloroperoxidase of curved spore.The chloroperoxidase that contains protoheme is to obtain (from dark brown Ka Er black mould) from Sigma.30 ℃ at 20mM pH5.5 sodium citrate buffer solution, 10mM sodium-chlor, 100 μ M hydrogen peroxide, in 50 μ M, the one chlorine methone with a chlorine methone (e 290nm=20.2mM
-1.cm
-1) be converted into dichloro methone (e 290nm=0.2mM
-1.cm
-1), use the spectrophotometric determination chloroperoxidase at Cl
-Be converted into the activity among the HOCl.The definition of the chloroperoxidase of a unit is the required enzyme amount of a chlorine methone (Sigma) that transforms 1 μ mol at per minute.Two kinds of enzymes are used identical analysis (with the activity definition), so that can when identical activity, determine the dosage of two kinds of enzymes.
Method:
Utilize aseptic technique, preparation is dissolved in 20mM pH5.5 sodium citrate buffer solution, in the 10mM sodium-chlor every milliliter about 10
7The suspension of bacterium.Getting the 1.9ml sample from this suspension joins the sterile test tube.Subsequently to obtain each 0.1ml of storage liquid that two kinds of dilution modes of enzyme add the chloroperoxidase that contains vanadium and contain the peroxidase of protoheme.The superoxol that adds 0.5ml 25mM then accurately is incubated 5 minutes at 30 ℃ with sample.Get the 1ml reaction mixture, join the cold BSA of 9ml (1%w/v) solution and place ice bath immediately, to stop the reaction of hypochlorite and microorganism.With sample from 10
-1Be diluted to 10
-5And 100 μ l samples of each diluent are placed on the BHI agar plate of mark and cultivate, be expressed as motility rate with the clonogenic unit (CFU) in every milliliter.At 30 ℃ flat board was cultivated 15-18 hour then.If do not detect CFU, then flat board was cultivated 24 hours again at 30 ℃.
The results are shown in the Table IV.Add fashionablely with identical activity even these results show significantly, the chloroperoxidase that contains vanadium also can provide than the more effective sanitation system of the chloroperoxidase that contains protoheme.
Table IV
??10mM?NaCl | Vanadium chloroperoxidase (U/ml) | Protoheme chloroperoxidase (U/ml) | Log reduction value |
Intestinal bacteria | ?????0.000 ?????0.00156 ?????0.0030 ?????0.0060 ?????0.012 ?????0.025 ?????0.050 ?????0.10 | ?????0.000 ?????0.00156 ?????0.0030 ?????0.0060 ?????0.012 ?????0.025 ?????0.050 ?????0.10 | 0.0 4.0 5.0 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 0.0 0.1 0.1 0.1 0.2 1.0 1.2 1.2 |
Harmless Li Site bacterium | ?????0.000 ?????0.00156 ?????0.0030 ?????0.0060 ?????0.012 ?????0.025 ?????0.050 ?????0.10 | ?????0.000 ?????0.00156 | 0.0 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 0.0 0.0 |
???0.0030 ???0.0060 ???0.012 ???0.025 ???0.050 ???0.10 | ????0.0 ????0.0 ????0.0 ????0.0 ????0.0 ????0.0 | ||
Streptococcus faecium | ????0.000 ????0.00156 ????0.0030 ????0.0060 ????0.012 ????0.025 ????0.050 ????0.10 | 0.000 0.00156 0.0030 0.0060 0.012 0.025 0.050 0.10 | 0.0 5.0 5.0 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 7.0 (==complete lethal) 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.9 |
The hydrogen peroxide in various sources is to the inhibiting influence of V-CPO
Among the embodiment in front, from storage liquid, add as the hydrogen peroxide of one of V-CPO reaction substrate.The effect of the hydrogen peroxide in other source has been described in this embodiment.In a biological oxygen monitor YSI5300 type (oxygen storehouse 5301), analyze oxydase at 30 ℃, wherein utilize the consumption of pH5.5 citrate buffer solution (20mM Trisodium Citrate-sodium hydrate buffer solution+10mM sodium-chlor) as damping fluid monitoring oxygen.At 30 ℃ with this damping fluid of air saturation.Utilize the substrate of 15g/l (final concentration) glucose as glucose oxidase.The bacterial isolates of Shi Yonging is intestinal bacteria NCTC900 in this embodiment.Soak in juice (BHI) broth culture at the brain heart, 30 ℃ with microbial culture 15-18 hour.After cultivating, with bacterial strain washed twice in pH5.5 citrate buffer solution (20mM trisodium citrate-NaOH damping fluid+10mM NaCl).With bacterial suspension centrifugal on the Eppendorf whizzer (14000rpm, 5 minutes), remove supernatant liquor then and subsequently bacterial precipitation is suspended in the citrate buffer solution.Repeat this washing step once for various bacterial suspensions then.Then with the pH5.5 citrate buffer solution dilute this through the bacterial suspension of twice washing to obtain every milliliter about 10
8The suspension of bacterium.Carry out in the process at washing step, cell remains in the ice bath.With damping fluid and BSA solution (1%w/v is dissolved in the pH5.5 citrate buffer solution) filtration sterilization and be stored in 4 ℃.By with the dilution of aseptic deionized water from storage liquid (107,000ppm) preparation hypochlorite solutions.By preparing superoxol from 30% storage liquid with the aseptic deionized water dilution.Casein hydrolysate obtains from Difco.Method according to people (1993) such as Van Schijndel never waits mould separation of curved spore and purifying chloroperoxidase.From the glucose oxidase of Sigma acquisition from aspergillus niger.
Method:
Utilize aseptic technique, preparation is dissolved in every milliliter about 10 in the pH5.5 citrate buffer solution
8The suspension of bacterium.Getting the 1.3ml sample from this suspension joins the aseptic reaction vessel, stir continuously with the bar magnet agitator at whole experimental session, 0.5mg/ml casein hydrolysate (the being dissolved in the pH5.5 citrate buffer solution) solution that adds 0.5ml subsequently adds V-CPO solution 0.2ml to obtain the hypochlorite that final concentration is 6.5ppm in this reaction vessel.Blank determination is only to add the sterile buffer of 0.2ml to substitute the V-CPO solution of 0.2ml.At 30 ℃ reaction vessel is incubated.Add following three kinds of each 0.5ml of peroxidation hydrogen generation system subsequently:
1. store the hydrogen peroxide of liquid from 3mM;
2. store the Sodium Hydrogen Carbonate of liquid from 3mM;
3. the mixture of glucose oxidase (0.39U/ml) and 75mg/ml glucose.
At 30 ℃ sample accurately is incubated 5 minutes.Get the 1ml reaction mixture, join the cold BSA of 9ml (1%w/v) solution and place ice bath immediately, to stop the reaction of hypochlorite and microorganism.With sample from 10
-1Be diluted to 10
-5And 100 μ l samples of each diluent are placed on the BHI agar plate of mark and cultivate, (CFU) is expressed as motility rate with every milliliter of clonogenic unit.At 30 ℃ flat board was cultivated 15-18 hour then.If do not detect CFU, then flat board was cultivated 24 hours again at 30 ℃.Value that is obtained and the MIC value that the hypochlorite that uses a Micropump to add same amount obtains are compared.This step is finished as follows:
Utilize aseptic technique, preparation is dissolved in every milliliter about 10 in the pH5.5 citrate buffer solution
8The suspension of bacterium.Getting the 1.3ml sample from this suspension joins the aseptic reaction vessel, stir continuously with the bar magnet agitator at whole experimental session, casein hydrolysate (being dissolved in the 0.5mg/ml pH5.5 citrate buffer solution) solution that adds 0.5ml subsequently adds the aseptic pH5.5 citrate buffer solution solution of 0.2ml then.The hypochlorite solutions effluent (flow velocity 0.1ml/ minute) of sample 0.5ml32.5ppm on then in 30 ℃ of times of 5 minutes.Get the 1ml reaction mixture after being incubated 5 minutes, join the cold BSA of 9ml (1%w/v) solution and place ice bath immediately, to stop the reaction of hypochlorite and microorganism.With sample from 10
-1Be diluted to 10
-6And 100 μ l samples of each diluent are placed on the BHI agar plate of mark and cultivate, be expressed as motility rate with the clonogenic unit (CFU) in every milliliter.At 30 ℃ flat board was cultivated 15-18 hour then.If do not detect CFU, then flat board was cultivated 24 hours again at 30 ℃.The results are shown in the Table V.The hydrogen peroxide of Table V different sources and the reaction of V-CPO
The hydrogen peroxide source | The concentration of casein hydrolysate (mg/ml) | The reduction of log value when the 6.5ppm hypochlorite | The reduction of log value during the 6.5ppm hypochlorite that produces by enzymatic |
Hydrogen peroxide storage liquid | ?????0.0 | (8.2=complete lethal) | (8.0=complete lethal) |
Hydrocarbonate | ?????0.0 | (8.0=complete lethal) | (8.2=complete lethal) |
Glucose oxidase | ?????0.0 | (6.4=complete lethal) | (6.4=complete lethal) |
Hydrogen peroxide storage liquid | ?????0.1 | ???????1.0 | (8.0=complete lethal) |
Hydrocarbonate | ?????0.1 | ???????0.8 | (8.2=complete lethal) |
Glucose oxidase | ?????0.1 | ???????1.0 | (6.4=complete lethal) |
Determine chloroperoxidase gene (cDNA) encoding sequence method and from not waiting mould gene of curved spore (Centraal Bureau voor Schimmelcultules, rheNetherlands, strain No 102.42) and possible expression system
Method according to people (1993) such as Van Schijndel never waits the mould liquid culture of curved spore to separate and the purifying chloroperoxidase, and different is to use FPLC system (Pharmacia LKB) to carry out two other purification steps after the DEAE chromatography.At first use phenyl-Sepharose Cl-4B hydrophobic interaction post desmoenzyme in the presence of the 2M NaCl in being dissolved in 50mM Tris-HCl (pH8.3), the gradient of using the 2MNaCl from be dissolved in 50mM Tris-HCl (pH8.3) to descend is subsequently carried out wash-out.For last purification step,, carry out wash-out with the 0M-0.5M NaCl that is dissolved among 20mM piperazine-HCl (pH5.4) subsequently with MonoQ HR 5/5 anion-exchange column (ex Pharmacia) desmoenzyme.Utilize rotary evaporation that enzyme is concentrated subsequently, subsequently at 50mM Tris-SO
4Dialysis in the damping fluid (pH8).Use SP V8 and trypsinase enzymatic digestion respectively according to standard method known in the art, perhaps use CNBr chemical cracking (Gross, E. (1976), Methods Enzymology 11,238-255) chloroperoxidase of purifying.According to Laemmli (Laemmli, U.K. (1970) Nature227,680-685) utilize SDS-PAGE that the peptide that obtains is separated or separates on the Wheat flavone gel with the method for Von Jagow (1987) according to Schagger, CAPS transfering buffering liquid (the 10mM 3-(hexahydroaniline)-1-propane yellow acid that utilizes Matsudaira (1987) to describe then, 10% methyl alcohol PH11) is transferred to (Immobilon-P ex Millipore on the pvdf membrane.Behind electrophoresis elution, this film was embathed 5 minutes, at room temperature dyeed 5 minutes, and at 50% methyl alcohol, decolouring is 10 minutes and air-dry in 10% acetate with the 0.1% Coomassie brilliant blue R-250 that is dissolved in 50% methyl alcohol with distilled water.(Backman Instruments, Inc. USA) carries out the Edmann automatic sequencing with the peptide bands of a spectrum with Porton LF 3000 protein sequencers.The determined amino acid sequence result is summarized in Fig. 1.
Design the oligonucleotide (seeing Table VII) of complete degeneracy according to the aminoacid sequence of this peptide, utilize the first chain cDNA in polymerase chain reaction (PCR), to use the primer of these degeneracys as template.The first chain cDNA is by being prepared as follows: for isolation of RNA, will not wait the mould spore inoculating of curved spore in a kind of fermention medium, every liter of this fermention medium contains trace element solution people such as (, (1993)) Van Schijndel of 4 gram yeast extracts and 2ml.After growth several days by filtering collection mycelium and freeze-drying.In liquid nitrogen, the freeze dried mould mycelium of curved spore that do not wait is ground.Extract damping fluid (42mM Trisodium Citrate PH7,8.3%M-Sarkosyl L, 50mM beta-mercaptoethanol, 1%Triton x-100 and 4M guanidinium isothiocyanate) by adding RNA, and at room temperature be incubated 1 hour extraction RNA.Add the 2M sodium acetate (PH4) of 0.1 part of volume and the phenol of a volume: chloroform: primary isoamyl alcohol (25: 24: 1) and this mixture placed 15 minutes on ice.After centrifugal 10 minutes of 10000 * g (4 ℃), collect water, add the dehydrated alcohol of 1 times of volume and subsequently with 10000 * g carried out centrifugal in 1 hour this mixture insulation at-20 ℃.The RNA that this precipitation is suspended in suitable volumes again extracts in the damping fluid and surpass centrifugal classification people such as (, 1989) Sambrook in the cesium chloride gradient.Should precipitate and wash carefully and be stored in 75% ethanolic soln at-70 ℃.For separating mRNA, with RNA precipitation and be suspended in again in the water that does not have the RNA enzyme, (Promega company USA) extracts mRNA to use polyAtract mRNA separating kit afterwards.Utilize the Pharmacia first chain cDNA synthetic agent box (Pharmacia BioTech) never waiting the synthetic first chain cDNA on the mould isolating mRNA of curved spore.Aminoacid sequence according to the chloroperoxidase peptide designs 4 20 aggressiveness degenerate oligonucleotides (referring to Table VII) and is being used as primer not wait in the mould polymerase chain reaction of the first chain cDNA as template of curved spore.Utilize thermal cycler (Eppemdorfmastercycler5330) and Taq polysaccharase (Promega company) to finish polymerase chain reaction.Obtain maximum amplification for the primer that utilizes these degeneracys makes the cDNA of coding chloroperoxidase, make polymerase chain reaction circulation 30 times at 46 ℃ (annealing steps).Two specific fragments that obtain are connected on the pUC18 carrier, and the clone also checks order to two chains, according to two kinds of special primers below the dna sequencing consequence devised:
5’-CATAGCGATAGCGACGCGGA-3’
With
5’-CTAACCCCGGCGCCAACATC-3’
These two kinds of primers are used for the polymerase chain reaction as template with the first chain cDNA.Therefore obtain the gene specific dna fragmentation by connecting two known dna sequence dnas.This fragment cloning to the pUC18 carrier, is checked order subsequently.In order the 5 ' district of the mRNA of the chloroperoxidase that obtains to encode to use 5 ' amplification RACE test kit (Clometech company).Saidly never wait curved spore to separate the chloroperoxidase genomic gene in mould by following: freeze driedly not wait the mould mycelium of curved spore to separate not wait the mould genomic dna of curved spore from what liquid nitrogen, grind, and extraction damping fluid (200mM Tris-HCl with appropriate amount, PH8.5,25mMEDTA, 250mM NaCl, 1%SDS and 0.2mg/ml Proteinase K) extract.At room temperature after the incubated overnight, add the phenol of 0.7 volume and the chloroform of 0.3 volume and thoroughly mix.With 10000 * g centrifuge tube and water layer is transferred in the test tube of a cleaning.Dehydrated alcohol precipitation genomic dna with 2 times of volumes.After centrifugal 5 minutes with 5000 * g.Again the 10mM Tris-HCl that is suspended in 2ml, pH8.0,1mM EDTA will be precipitated.And recommendation RNA enzyme (Boehringer, Mannheim) processing by manufacturers.Use phenol: chloroform: primary isoamyl alcohol (25: 24: 1) extracts the solution that contains genomic dna, after ethanol sedimentation, is dissolved in the 10mM Tris-HCl of suitable volumes at last, and pH8.0 is in the 1mM edta buffer liquid.For the Southern that carries out genomic dna analyzes, unite dna digestions with several limit endoenzymes, after agarose gel electrophoresis, inhale and print on the nitrocellulose filter (Sambrook et al., 1989).Utilize radiolabeled specific fragment (two special primers with above group description increase) to finish hybridization, said fragment causes at random with the dATP (Sambrook et al., 1989) of α-32P mark.Prepare little library based on the result who obtains with the genomic dna that is inserted into the PstI digestion on the pUC18 carrier.Screen this library with analyzing identical probe with Southern.Separate positive colony and also two chains are checked order confirmation cDNA sequencing result.Having provided coding in Fig. 2 does not wait the gene of the mould chloroperoxidase of curved spore and infers gene product.
The chloroperoxidase that is prepared as follows cereuisiae fermentum produces system:
From wild-type cereuisiae fermentum GAL1 gene (Molecular and Cellular Biology 10,4757-4769,1990) obtain the known GAL1 induction type of EcoR1-BamH1 fragment Yeast promoter, and be cloned into plasmid YCplac33 and YEplac95 (Gietz and Sugino (1988) Gene 74, EcoR1 527-534), BamH1 site respectively.The plasmid that is obtained is called TNT1 and TNT2.By utilizing the PstI-EcoRI5 ' fragment that do not wait curved spore mould chloroperoxidase gene of subclone in the pUC18 to carry out the PCR experiment as primer and at BamH1 restriction site of the front of the 5 ' starting point that does not wait the mould chloroperoxidase gene of curved spore preparation as template with M13/pUC22-aggressiveness reverse sequence primer, and primer is in the front of the 5 ' starting point that does not wait the mould chloroperoxidase gene of curved spore:
5’GAG?AGA?GGA?TCC?ACT?CAC?TAC?TTA?CAA?TCA?CAC3’
Fragment with EcoR1 and BamH1 digest amplification.The pUC18 that digests to EcoR1-SmaI from the EcoRI-PvuII fragment subclone that does not wait the mould chloroperoxidase gene of curved spore that will contain 3 ' part of this gene.After EcoRI and XbaI digestion, go out to contain not wait the mould chloroperoxidase gene 3 ' part of curved spore from this clone purification.
According to the method known in the art plasmid TNT3 and TNT4 transformed yeast bacterial strain BJ1991 and selection ura+ transformant.The ura+ transformant is copied on the YP flat board that contains glucose (2%) and semi-lactosi (2%).After growth, obtain cell and be suspended in 200 μ l 20mM Tris-HCl again, among the pH8.1 from flat board.After cultivating 5 minutes, get 10 μ l liquid and point sample to nitrocellulose filter.At 100mM sodium acetate buffer (pH5.5), the positive dianisidine of 1mM is incubated nitrocellulose filter in 100mM KBr and the 2mM hydrogen peroxide.The yeast strain that grows in semi-lactosi have a few and observe clearly color and generate, and grow in glucose yeast strain have a few and do not observe color.This shows made up the semi-lactosi induction type production system that does not wait the mould chloroperoxidase gene of curved spore in cereuisiae fermentum.Use 100mM potassium phosphate buffer (pH6.5), the similar analysis that 100mM KBr and 1mM hydrogen peroxide and 40 μ M phenol red (BDH) carry out clearly illustrates that the liquid from the yeast strain that grows in semi-lactosi forms indigo plant/purple, and is used for not having change in color from the liquid that grows in the yeast strain of glucose.Has the allos chloroperoxidase expression of gene system that does not wait the mould chloroperoxidase function of curved spore that is similar in order further to confirm in yeast, to have produced to express, from the yeast strain purification of Recombinant enzyme of semi-lactosi inductive TNT3 or TNT4 conversion.On containing the substratum of semi-lactosi, after the growth, collect yeast cell and be suspended in 20mM Tris-HCl again, (pH8.1) in.Add aseptic granulated glass sphere then, suspension thoroughly vibrates.After centrifugal 15 minutes with 10,000 * g, obtain supernatant liquor and be added on the DEAE post, utilize to be substantially similar to this recombinase of purification process purifying that wild-type does not wait the mould enzyme of curved spore (above).After purifying, obtaining specific activity is that the proteinic reorganization chloroperoxidase of 22U/mg is (at 100mM sodium acetate buffer pH5.0, the 1mM hydrogen peroxide, measure among 5mM Repone K and the 50 μ M MCD, also can be referring to van Schijndel et al., 1993), it is equivalent to never to wait the proteinic specific activity of 20U/mg of the chloroperoxidase of the mould purifying of curved spore own.The active situation of pH that in accompanying drawing 3, has shown wild-type chloroperoxidase and reorganization chloroperoxidase.The enzyme that accompanying drawing 3 further provides recombination yeast to produce has the function that is similar to wild-type enzyme.
The suitable halo peroxidase of screening in other microorganism
The microorganism of Shi Yonging is not wait curved spore mould (CBS 371.72) in the present embodiment, Drechslera biseptata (CBS 371.72), Drechslera fuqax (CBS 509.77), Drechslera nicotiae (CBS 655.74), Drechslera subpapendorfii (656.74), Embelisia hyacinthi (416.71), Embelisia didymospora (CBS 766), Ulocladium chartarum (200.67) and Ulocladium botrytis (452.72).Various fungies are grown on agar plate.To nitrocellulose filter, this filter membrane soaks in 50mM Tris-HCl damping fluid (8.3) in advance after growth is finished, extracellular protein to be shifted (duplicate and inhale seal).After on agar plate, cultivating 15 minutes, by being with or without in the presence of the 0.1M Potassium Bromide filter membrane at 100mM sodium acetate (5.5) or potassium phosphate buffer (pH6.5 and 7.5), imbibition in positive dianisidine of 1mM and the 2mM hydrogen peroxide and detect the halo peroxidase activity of filter membrane.Therefore can detect the bromine peroxide enzyme and/or the chloroperoxidase of generation.For whether the halo peroxidase that detects generation is the halo peroxidase that contains vanadium, repeat above-described detection in the presence of the 10 and 100 μ M vanadic acid sodiums having and do not have.For the halo peroxidase that contains vanadium, under the situation of replenishing vanadate, observe the growth signal.Whether be similar to the vanadium-halogenated peroxidase that does not wait curved spore mould really in order to detect the chloroperoxidase that identifies, according to van Schijndel et al., 1993 method is from Ulocladiumchartarum, Embelisia didymospora, the chloroperoxidase of Drechslera subpapendorfii purify small quantities.The optimal pH of these enzymes is 4.5-5.5.Increase owing to add the chlorization activity of these enzymes of vanadic salts, obviously the peroxidase of vanadium-halogenated really of these enzymes.Whether be similar to and do not wait the mould chloroperoxidase of curved spore in order further to detect these enzymes of being discerned, further carry out qualitative a kind of halo peroxidase of being discerned.Select chloroperoxidase by fungi Drechslera biseptata (CBS 371.72) generation for this reason.It has and is similar to the characteristic that does not wait the mould chloroperoxidase of curved spore, has high thermal stability and to the high-affinity of its substrate.For other vanadium-halogenated peroxidase (de Boer et al., 1988; Wever etal., 1988), oxidized enzyme does not have epr signal; But after the SODIUM HYDROSULPHITE sodium reduction, observe typical vanadium base EPR spectrum (result does not show).Isotropy EPR parameter g
0=1.969 and A
0=9.0 almost with identical (Wever et al, 1985) of not waiting the mould enzyme of curved spore.In addition, utilize proteolytic enzyme and cyanogen bromide the enzymatic lysis of purifying to be peptide.Peptide structure collection of illustrative plates shows identical form, shows that these two kinds of enzymes have very big sequence homology.Really for this situation, two peptide chains of the enzyme that obtains with protease treatment and purifying are checked order.This two sequence shows very large homology and can sum up two kinds of enzymes is very similar.
Derive from the aminoacid sequence that does not wait the mould peptide of curved spore:
(Asp)-leu-arg-gln-pro-tyr-asp-pro-thr-ala-pro-ile-glu-asp-gln-pro-gly-ile-val-arg-thr-
Aminoacid sequence from the similar peptide of Drechslera biseptata:
Asp-leu-arg-gln-pro-tyr-asp-pro-thr-ala-pro-ile-glu-glu-gln-pro-gly-ile-val-arg-thr-
Therefore by using replica technique (after adding vanadic salts, detecting active the raising) and/or can differentiating the suitable vanadium-halogenated peroxidase that contains by (part) purifying enzyme and in the raising of detection of active afterwards of adding vanadic salts.
Utilize the further suitable chloro peroxidase of screening in other microorganism of antibody
The bacterial strain of Shi Yonging is not wait curved spore mould (CBS102.42) in the present embodiment, Drechslera biseptata (CBS 371.72), Drechslerasubpapendorfii (CBS 656.74), Embelisia didymospora (CBS 766.79), UloCladium chartarum (200.67).Microorganism is pressed two growth periods.At first, use the spore inoculating sterile propagation substratum (Van Schijndel et al., 1993) of microorganism.23 ℃ of shaking culture 3 days, culture is transferred to contained in 1 liter of fermention medium, 3 liters of triangular flasks of (containing 5 gram caseins (Gibco BRL) in every liter of distilled water, 3 gram yeast extracts and 1 gram fructose) afterwards.After 23 ℃ of shaking culture 14-17 days, collect substratum, filter and substantially according to Van Schijndel et al. 1994 method purifying chloroperoxidase.The preparation antivenom purification is (according to Van Schijndel et al. in a rabbit (does at two monthly ages), 1994 method) the polyclonal antibody that does not wait the mould chloroperoxidase of curved spore (the complete auxiliary agent of Fu Shi is used in injection for the first time, and the incomplete auxiliary agent of Fu Shi is used in booster shots).Booster shots were got blood from rabbit in 6 days afterwards the last time.At 56 ℃ serum is heated 30 minutes so that complement inactivation and centrifugal then.Obtain supernatant liquor.The bromine peroxide enzyme for preparing various purifying chloroperoxidases and Ascophylum nodosrm is (according to Wever et al, 1985 purifying) serial dilutions, each protein (about 0.1mg/ml) since 50 μ l, and each sample dilutes twice successively.Utilize a dot blotting instrument (Bio-Rad) on nitrocellulose filter, to put diluent, with the 2%BSA washing and successively with the anti-chloroperoxidase serum of rabbit, biotinylated goat antirabbit (diluting 1: 3000), 1: 800 diluent and the developer (5-bromo-4-chloro-3-indoles phosphoric acid, 4-nitroblue tetrazolium drone muriate) (Boehinger Mannheim) of alkaline phosphate bonded streptavidin (diluting 1: 2000) are incubated.All steps are carried out according to standard method.The results are shown in the Table VI.
Table VI
The halo peroxidase comes from | Do not wait the polyclonal antibody of the mould chloroperoxidase of curved spore that cross reaction is arranged with anti- |
Do not wait curved spore mould | Be |
????Drechslera?biseptata | Be |
??Drechslera?subpapendorfii | Be |
????Embelisia?didymospora | Be |
?????Ulocladium?chartarum | Be |
Bromine peroxide enzyme from Ascophylum nodosrm | Not |
Based on disclosed result in the Table VI, can sum up the chloroperoxidase that carries out with the anti-antibody that does not wait the mould chloroperoxidase of curved spore and be suitable for discerning other suitable halo peroxidase that contains vanadium.These halo peroxidase can be rough forms, part or all of purified form.Purification technique is a technology known in the art, as gel-filtration, and ion exchange chromatography, hydrophobic interaction chromatography, precipitation technology, (surpassing) filtering technique, affinity chromatography, gel electrophoresis and other technology.
The suitable chloroperoxidase of screening in other microorganism
Described what use is made of in the present embodiment and in other microorganism, detected homologous gene from the radioactive probe that does not wait the mould chloroperoxidase gene of curved spore.Can finish as described below:
Substantially do not wait curved spore mould (CBS102.42) according to the purification process that does not wait the mould chromosomal DNA of curved spore (being described in embodiment 6) purifying, Drechslera biseptata (CBS 371.72), Embelisia didymospora (CBS 766.79), chromosomal DNA.Southern for genomic dna analyzes, and prints on the Nitrocellulose filter membrane (Sambrook et al., 1989) in conjunction with digesting this DNA, inhaling after agarose gel electrophoresis with several Restriction Enzymes.Utilize radiolabeled gene specific fragment to hybridize, described fragment utilize α-
32The dATP of P mark (Sambrook et al., 1989) causes at random.Utilize the first chain cDNA (referring to embodiment 6) as template and use following primer (before radio-labeling) the employed gene specific fragment that in polymerase chain reaction, increases:
5’-CACGATGGGGTCCGTTACAC
With
5’-GTACCGCTATCGCTGCGCCTG
Hybridization conditions is as follows:
In prehybridization and hybridization, utilize 6 * SSPE, 5 * Denharts, 0.5%SDS and 10mg salmon sperm dna are as damping fluid.55 ℃ of prehybridizations 1 hour.Then radioactive probe is boiled and directly added again in 1 minute.Continuing hybridization subsequently spends the night.Provided in the accompanying drawing 4 with not waiting radioautogram that curved spore is mould and Drechslera biseptata obtains.In the figure, swimming lane 1: λ DNA; Swimming lane 2: non-digestion do not wait the mould genomic dna of curved spore; Swimming lane 3:idem digests with EcoRI; Swimming lane 4: digest with BamH1; Swimming lane 5: with EcoRI and BamH1 digestion; Swimming lane 6: digest with XbaI; Swimming lane 7: digest with PstI; Swimming lane 8: with XbaI and PstI digestion; Swimming lane 9-14: use Drechslera biseptata, idem.As seeing in the figure, use chromosomal DNA to obtain positive colony from Drechslera biseptata, show that two kinds of gene height are similar.Use DNA to obtain analog result from Embelisiadidymospora.Therefore we sum up to utilize and do not wait the mould chloroperoxidase gene of curved spore, or this gene deutero-part or can detect the vanadium-halogenated peroxidase of two kinds of other microorganisms based on the probe of the sequence preparation that does not wait the mould chloroperoxidase gene of curved spore.
Table VII is based on two kinds of Oligonucleolide primers (20 aggressiveness) that do not wait the mould chloroperoxidase aminoacid sequence of curved spore.
I: inosine
A/G: use at this position A and impartial mixing of G.
C/T: use at this position C and impartial mixing of T.
G/A/T/C: at this position G, A, the impartial mixing of C and T uses.
Oligonucleotide 1:
5’??-TAC/TATGAAA/GCCIGTIGAA/GCA-3’
Oligonucleotide 2:5 '-AG/AT/CTGGCG/ATAIGCG/ATTG/ATC-3 '
Oligonucleotide 3:5 '-GAC/TGAA/GACIGCIGAA/GTAC/TGA-3 '
Oligonucleotide 4:5 '-AG/AIGCT/CTGIGCICCG/A/T/CCCCAT-3 '
Claims (13)
1. the enzymatic antimicrobial composition contains the vanadium-halogenated peroxidase, halogenide and hydrogen peroxide cource or hydrogen peroxide cource.
2. the enzymatic antimicrobial composition of claim 1, wherein the vanadium-halogenated peroxidase is a chloroperoxidase.
3. the enzymatic antimicrobial composition in the arbitrary claim in front, wherein the vanadium-halogenated peroxidase is the chloroperoxidase that never waits the mould acquisition of curved spore.
4. the enzymatic antimicrobial composition in the arbitrary claim in front, wherein the vanadium-halogenated peroxidase is a chloroperoxidase, it has immunological cross-reaction with the chloroperoxidase that never waits the mould CBS102.42 of curved spore to obtain.
5. the enzymatic antimicrobial composition in the arbitrary claim in front, wherein hydrogen peroxide cource is an enzymatic hydrogen peroxide generation system.
6. the enzymatic antimicrobial composition of claim 5, wherein enzymatic hydrogen peroxide generation system is means of glucose/glucose oxidase or lactic acid/Lactate Oxidase system.
7. the enzymatic antimicrobial composition in the arbitrary claim in front, described composition does not have the katalaze enzyme activity basically.
8. suppress the method for microorganism growth, comprise the front described composition of arbitrary claim is applied to surface to be sterilized.
9. the vanadium-halogenated peroxidase is as the application of sanitizer.
10.DNA sequence contains the structure gene of coding from the vanadium chloroperoxidase that does not wait the mould CBS102.42 of curved spore.
11.DNA sequence as shown in Figure 2, contains the structure gene of coding from the vanadium chloroperoxidase that does not wait the mould CBS102.42 of curved spore.
12. expression vector contains a replication origin, transcribes and stop the control sequence and the part of claim 10 or 11 dna sequence dna at least.
13. prepare the method for vanadium-halogenated peroxidase, comprise that the expression vector with claim 12 transforms appropriate host, under the condition that allows expression of structural gene, cultivate the host and separate the vanadium-halogenated peroxidase.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94200893.9 | 1994-03-31 | ||
EP94200893 | 1994-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1146782A true CN1146782A (en) | 1997-04-02 |
Family
ID=8216755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95192407A Pending CN1146782A (en) | 1994-03-31 | 1995-03-31 | Enzymatic antimicrobial compositions |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0753055A1 (en) |
JP (1) | JPH09511396A (en) |
CN (1) | CN1146782A (en) |
AU (1) | AU2215495A (en) |
BR (1) | BR9507226A (en) |
CA (1) | CA2182966A1 (en) |
CZ (1) | CZ288041B6 (en) |
HU (1) | HUT74967A (en) |
NL (1) | NL9401048A (en) |
PL (2) | PL181389B1 (en) |
SK (1) | SK123096A3 (en) |
WO (1) | WO1995027046A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1327772C (en) * | 2001-12-04 | 2007-07-25 | 诺和酶股份有限公司 | Methods for killing spores |
CN101827527A (en) * | 2007-10-23 | 2010-09-08 | 诺维信公司 | Methods for killing spores and disinfecting or sterilizing devices |
CN105120681A (en) * | 2013-05-08 | 2015-12-02 | 诺维信公司 | Animal feed enzymes |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE365208T1 (en) * | 1996-04-29 | 2007-07-15 | Novozymes As | LIQUID COMPOSITIONS CONTAINING NON-AQUEOUS ENZYMES |
EP0912097B1 (en) * | 1996-05-09 | 2002-08-07 | Novozymes A/S | Antimicrobial peroxidase compositions |
AU6469698A (en) * | 1997-03-24 | 1998-10-20 | Clorox Company, The | A chloroperoxidase enzyme system for generating hypochlorous acid and hypochlorite (in situ) |
WO1999002640A1 (en) * | 1997-07-09 | 1999-01-21 | The Procter & Gamble Company | Cleaning compositions comprising an oxidoreductase |
US6025186A (en) * | 1997-08-14 | 2000-02-15 | Novo Nordisk A/S | Reduction of malodor |
US6074631A (en) * | 1997-08-14 | 2000-06-13 | Novo Nordisk A/S | Reduction of malodour |
US6080391A (en) * | 1997-08-14 | 2000-06-27 | Novo Nordisk A/S | Reduction of malodour |
AU8623198A (en) | 1997-08-14 | 1999-03-08 | Novo Nordisk A/S | Antimicrobial composition containing a haloperoxidase, a hydrogen peroxide source, a halide source and an ammonium source |
US6228128B1 (en) | 1997-11-10 | 2001-05-08 | Charlotte Johansen | Antimicrobial activity of laccases |
US6656715B1 (en) | 1998-09-10 | 2003-12-02 | The Regents Of The University Of California | Recombinant minimal catalytic vanadium haloperoxidases and their uses |
US6232457B1 (en) | 1998-09-10 | 2001-05-15 | The Regents Of The University Of California | Recombinant vanadium haloperoxidases and their uses |
US6592867B2 (en) * | 1998-11-09 | 2003-07-15 | Novozymes A/S | Antimicrobial composition containing an oxidoreductase and an enhancer of the N-hydroxyanilide-type |
US7063970B1 (en) | 1999-05-06 | 2006-06-20 | Norozymes A/S | Enzymatic preservation of water based paints |
ATE417899T1 (en) * | 1999-05-06 | 2009-01-15 | Novozymes As | ENZYMATIC PRESERVATION OF AQUEOUS PAINTS |
EP1207747A1 (en) * | 1999-08-10 | 2002-05-29 | Novozymes A/S | Reduction of malodour in soiled animal litter |
WO2001011969A1 (en) * | 1999-08-13 | 2001-02-22 | Novozymes A/S | ENZYMATIC METHOD FOR KILLING OR INHIBITING MICROBIAL CELLS AT HIGH pH |
US6511835B1 (en) | 2000-04-14 | 2003-01-28 | Novozymes, A/S | Nucleic acids encoding polypeptides having haloperoxidase activity |
WO2001079463A2 (en) * | 2000-04-14 | 2001-10-25 | Novozymes A/S | Nucleic acids encoding polypeptides having haloperoxidase activity |
WO2001079461A2 (en) * | 2000-04-14 | 2001-10-25 | Novozymes A/S | Polypeptides having haloperoxidase activity |
US6410291B1 (en) | 2000-04-14 | 2002-06-25 | Novozymes A/S | Polypeptides having haloperoxidase activity |
AU2001246401A1 (en) * | 2000-04-14 | 2001-10-30 | Novozymes A/S | Polypeptides having haloperoxidase activity |
US6410292B1 (en) | 2000-04-14 | 2002-06-25 | Novozymes A/S | Nucleic acids encoding polypeptides having haloperoxidase activity |
US6509181B1 (en) | 2000-04-14 | 2003-01-21 | Novozymes, A/S | Polypeptides having haloperoxide activity |
AU2001246407A1 (en) | 2000-04-14 | 2001-10-30 | Maxygen, Inc. | Nucleic acids encoding polypeptides having haloperoxidase activity |
WO2002047483A1 (en) * | 2000-12-15 | 2002-06-20 | Novozymes A/S | Use of haloperoxidase, peroxide and carboxylic acid |
EP1497382A1 (en) * | 2002-04-12 | 2005-01-19 | Biolocus Aps | Antifouling composition comprising an enzyme in the absence of its substrate |
BRPI0810687B1 (en) | 2007-04-24 | 2018-02-06 | Novozymes North America, Inc. | PROCESS FOR PRODUCING A FERMENTATION PRODUCT FROM LIGNOCELLULOSE CONTAINING MATERIAL |
EP2362732B1 (en) * | 2008-10-23 | 2015-05-20 | Getinge Disinfection AB | A method of obtaining high-level disinfection in a washer disinfector, and a washer disinfector |
US20120020946A1 (en) | 2009-04-03 | 2012-01-26 | Novozymes A/S | Methods for Inactivating Viruses |
US20120034203A1 (en) | 2009-04-22 | 2012-02-09 | Novozymes A/S | Methods for Killing or Inhibiting Growth of Mycobacteria |
EP2510944A1 (en) * | 2011-04-15 | 2012-10-17 | National University of Ireland, Galway | Treatment of bacterial infections |
WO2013164429A1 (en) | 2012-05-02 | 2013-11-07 | Novozymes A/S | Enzymatic solubilization of metals |
US9902946B2 (en) | 2013-01-03 | 2018-02-27 | Novozymes A/S | Alpha-amylase variants and polynucleotides encoding same |
US20160024440A1 (en) | 2013-03-14 | 2016-01-28 | Novozymes A/S | Enzyme and Inhibitor Containing Water-Soluble Films |
CN111394202B (en) | 2013-04-23 | 2022-04-26 | 诺维信公司 | Liquid automatic dishwashing detergent composition with stabilized subtilisin |
WO2014177709A1 (en) | 2013-05-03 | 2014-11-06 | Novozymes A/S | Microencapsulation of detergent enzymes |
WO2014183921A1 (en) | 2013-05-17 | 2014-11-20 | Novozymes A/S | Polypeptides having alpha amylase activity |
US9926550B2 (en) | 2013-07-29 | 2018-03-27 | Novozymes A/S | Protease variants and polynucleotides encoding same |
WO2015150457A1 (en) | 2014-04-01 | 2015-10-08 | Novozymes A/S | Polypeptides having alpha amylase activity |
ES2813337T3 (en) | 2014-04-11 | 2021-03-23 | Novozymes As | Detergent composition |
WO2015181118A1 (en) | 2014-05-27 | 2015-12-03 | Novozymes A/S | Methods for producing lipases |
WO2015181119A2 (en) | 2014-05-27 | 2015-12-03 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
EP3164476A1 (en) | 2014-07-03 | 2017-05-10 | Novozymes A/S | Improved stabilization of non-protease enzyme |
WO2016079110A2 (en) | 2014-11-19 | 2016-05-26 | Novozymes A/S | Use of enzyme for cleaning |
US20180112156A1 (en) | 2015-04-10 | 2018-04-26 | Novozymes A/S | Laundry method, use of polypeptide and detergent composition |
EP3280800A1 (en) | 2015-04-10 | 2018-02-14 | Novozymes A/S | Detergent composition |
CN107835853B (en) | 2015-05-19 | 2021-04-20 | 诺维信公司 | Odor reduction |
WO2016202785A1 (en) | 2015-06-17 | 2016-12-22 | Novozymes A/S | Container |
US20180171271A1 (en) | 2015-06-30 | 2018-06-21 | Novozymes A/S | Laundry detergent composition, method for washing and use of composition |
EP3320089B1 (en) | 2015-07-06 | 2021-06-16 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
US20180171315A1 (en) | 2015-09-17 | 2018-06-21 | Novozymes A/S | Polypeptides having xanthan degrading activity and polynucleotides encoding same |
ES2794837T3 (en) | 2015-09-17 | 2020-11-19 | Henkel Ag & Co Kgaa | Detergent Compositions Comprising Polypeptides Having Xanthan Degrading Activity |
WO2017060493A1 (en) | 2015-10-07 | 2017-04-13 | Novozymes A/S | Polypeptides |
CN108291212A (en) | 2015-10-14 | 2018-07-17 | 诺维信公司 | Polypeptide variants |
WO2017066510A1 (en) | 2015-10-14 | 2017-04-20 | Novozymes A/S | Cleaning of water filtration membranes |
CN108431217B (en) | 2015-12-01 | 2022-06-21 | 诺维信公司 | Method for producing lipase |
US20190002819A1 (en) | 2015-12-28 | 2019-01-03 | Novozymes Bioag A/S | Heat priming of bacterial spores |
EP3433347B1 (en) | 2016-03-23 | 2020-05-06 | Novozymes A/S | Use of polypeptide having dnase activity for treating fabrics |
WO2017210188A1 (en) | 2016-05-31 | 2017-12-07 | Novozymes A/S | Stabilized liquid peroxide compositions |
CN109563449B (en) | 2016-06-23 | 2022-01-25 | 诺维信公司 | Uses, compositions and methods for soil removal of enzymes |
WO2018002261A1 (en) | 2016-07-01 | 2018-01-04 | Novozymes A/S | Detergent compositions |
WO2018007573A1 (en) | 2016-07-08 | 2018-01-11 | Novozymes A/S | Detergent compositions with galactanase |
EP3485010B1 (en) | 2016-07-13 | 2024-11-06 | The Procter & Gamble Company | Bacillus cibi dnase variants and uses thereof |
CN109996859B (en) | 2016-09-29 | 2021-11-30 | 诺维信公司 | Spore-containing particles |
WO2018060216A1 (en) | 2016-09-29 | 2018-04-05 | Novozymes A/S | Use of enzyme for washing, method for washing and warewashing composition |
US20210284933A1 (en) | 2016-10-25 | 2021-09-16 | Novozymes A/S | Detergent compositions |
CN110072986B (en) | 2016-11-01 | 2023-04-04 | 诺维信公司 | Multi-core particles |
EP3571279A1 (en) | 2016-12-01 | 2019-11-27 | Basf Se | Stabilization of enzymes in compositions |
WO2018108865A1 (en) | 2016-12-12 | 2018-06-21 | Novozymes A/S | Use of polypeptides |
WO2018184818A1 (en) | 2017-04-06 | 2018-10-11 | Novozymes A/S | Cleaning compositions and uses thereof |
US20200181542A1 (en) | 2017-06-30 | 2020-06-11 | Novozymes A/S | Enzyme Slurry Composition |
BR112020005558A2 (en) | 2017-09-20 | 2020-10-27 | Novozymes A/S | use of enzymes to improve water absorption and / or whiteness |
US11414814B2 (en) | 2017-09-22 | 2022-08-16 | Novozymes A/S | Polypeptides |
WO2019063499A1 (en) | 2017-09-27 | 2019-04-04 | Novozymes A/S | Lipase variants and microcapsule compositions comprising such lipase variants |
EP3697881B1 (en) | 2017-10-16 | 2024-12-18 | Novozymes A/S | Low dusting granules |
US20200318037A1 (en) | 2017-10-16 | 2020-10-08 | Novozymes A/S | Low dusting granules |
US20230416706A1 (en) | 2017-10-27 | 2023-12-28 | Novozymes A/S | Dnase Variants |
HUE057832T2 (en) | 2017-10-27 | 2022-06-28 | Procter & Gamble | Detergent compositions comprising polypeptide variants |
CN111868239A (en) | 2018-02-08 | 2020-10-30 | 诺维信公司 | Lipase, lipase variants and compositions thereof |
CN111757930A (en) | 2018-02-08 | 2020-10-09 | 诺维信公司 | Lipase variants and compositions thereof |
WO2019175240A1 (en) | 2018-03-13 | 2019-09-19 | Novozymes A/S | Microencapsulation using amino sugar oligomers |
EP3781660A1 (en) | 2018-04-17 | 2021-02-24 | Novozymes A/S | Polypeptides comprising carbohydrate binding activity in detergent compositions and their use in reducing wrinkles in textile or fabric |
EP3781680A1 (en) | 2018-04-19 | 2021-02-24 | Novozymes A/S | Stabilized cellulase variants |
WO2019201783A1 (en) | 2018-04-19 | 2019-10-24 | Novozymes A/S | Stabilized cellulase variants |
WO2019238761A1 (en) | 2018-06-15 | 2019-12-19 | Basf Se | Water soluble multilayer films containing wash active chemicals and enzymes |
EP3861008A1 (en) | 2018-10-03 | 2021-08-11 | Novozymes A/S | Polypeptides having alpha-mannan degrading activity and polynucleotides encoding same |
WO2020114965A1 (en) | 2018-12-03 | 2020-06-11 | Novozymes A/S | LOW pH POWDER DETERGENT COMPOSITION |
WO2020127796A2 (en) | 2018-12-21 | 2020-06-25 | Novozymes A/S | Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same |
MX2021011287A (en) | 2019-03-21 | 2021-10-13 | Novozymes As | Alpha-amylase variants and polynucleotides encoding same. |
US12247237B2 (en) | 2019-04-10 | 2025-03-11 | Novozymes A/S | Polypeptide variants |
BR112021020439A2 (en) | 2019-04-12 | 2022-05-24 | Novozymes As | Stabilized variants of glycoside hydrolase |
CN114207123A (en) | 2019-07-02 | 2022-03-18 | 诺维信公司 | Lipase variants and compositions thereof |
EP4022019A1 (en) | 2019-08-27 | 2022-07-06 | Novozymes A/S | Detergent composition |
CN114616312A (en) | 2019-09-19 | 2022-06-10 | 诺维信公司 | detergent composition |
WO2021064068A1 (en) | 2019-10-03 | 2021-04-08 | Novozymes A/S | Polypeptides comprising at least two carbohydrate binding domains |
WO2021105330A1 (en) | 2019-11-29 | 2021-06-03 | Basf Se | Compositions and polymers useful for such compositions |
US20220411773A1 (en) | 2019-12-20 | 2022-12-29 | Novozymes A/S | Polypeptides having proteolytic activity and use thereof |
EP3892708A1 (en) | 2020-04-06 | 2021-10-13 | Henkel AG & Co. KGaA | Cleaning compositions comprising dispersin variants |
US20230143128A1 (en) | 2020-04-08 | 2023-05-11 | Novozymes A/S | Carbohydrate binding module variants |
US20230167384A1 (en) | 2020-04-21 | 2023-06-01 | Novozymes A/S | Cleaning compositions comprising polypeptides having fructan degrading activity |
EP3907271A1 (en) | 2020-05-07 | 2021-11-10 | Novozymes A/S | Cleaning composition, use and method of cleaning |
CN115836125A (en) | 2020-06-24 | 2023-03-21 | 诺维信公司 | Use of cellulase for removing dust mites from textiles |
EP3936593A1 (en) | 2020-07-08 | 2022-01-12 | Henkel AG & Co. KGaA | Cleaning compositions and uses thereof |
EP4204551A2 (en) | 2020-08-25 | 2023-07-05 | Novozymes A/S | Variants of a family 44 xyloglucanase |
JP2023544111A (en) | 2020-09-22 | 2023-10-20 | ビーエーエスエフ ソシエタス・ヨーロピア | Improved combinations of proteases and protease inhibitors, including a second enzyme |
WO2022074037A2 (en) | 2020-10-07 | 2022-04-14 | Novozymes A/S | Alpha-amylase variants |
EP4232539A2 (en) | 2020-10-20 | 2023-08-30 | Novozymes A/S | Use of polypeptides having dnase activity |
US20230399588A1 (en) | 2020-10-28 | 2023-12-14 | Novozymes A/S | Use of lipoxygenase |
WO2022106404A1 (en) | 2020-11-18 | 2022-05-27 | Novozymes A/S | Combination of proteases |
WO2022106400A1 (en) | 2020-11-18 | 2022-05-27 | Novozymes A/S | Combination of immunochemically different proteases |
WO2022162043A1 (en) | 2021-01-28 | 2022-08-04 | Novozymes A/S | Lipase with low malodor generation |
WO2022171780A2 (en) | 2021-02-12 | 2022-08-18 | Novozymes A/S | Alpha-amylase variants |
EP4305146A1 (en) | 2021-03-12 | 2024-01-17 | Novozymes A/S | Polypeptide variants |
US20240060061A1 (en) | 2021-03-15 | 2024-02-22 | Novozymes A/S | Dnase variants |
EP4060036A1 (en) | 2021-03-15 | 2022-09-21 | Novozymes A/S | Polypeptide variants |
WO2022268885A1 (en) | 2021-06-23 | 2022-12-29 | Novozymes A/S | Alpha-amylase polypeptides |
CN118660951A (en) | 2022-03-02 | 2024-09-17 | 诺维信公司 | Use of xyloglucanases to improve the sustainability of detergents |
WO2023165950A1 (en) | 2022-03-04 | 2023-09-07 | Novozymes A/S | Dnase variants and compositions |
CN118974228A (en) | 2022-04-08 | 2024-11-15 | 诺维信公司 | Hexosaminidase variants and compositions |
EP4309500A1 (en) * | 2022-07-18 | 2024-01-24 | Acies Bio d.o.o. | Peroxidase based biocontrol agents |
WO2024017883A1 (en) * | 2022-07-18 | 2024-01-25 | Acies Bio D.O.O. | Peroxidase based biocontrol agents |
WO2024126483A1 (en) | 2022-12-14 | 2024-06-20 | Novozymes A/S | Improved lipase (gcl1) variants |
WO2024131880A2 (en) | 2022-12-23 | 2024-06-27 | Novozymes A/S | Detergent composition comprising catalase and amylase |
WO2024156628A1 (en) | 2023-01-23 | 2024-08-02 | Novozymes A/S | Cleaning compositions and uses thereof |
WO2024194245A1 (en) | 2023-03-21 | 2024-09-26 | Novozymes A/S | Detergent compositions based on biosurfactants |
WO2024213513A1 (en) | 2023-04-12 | 2024-10-17 | Novozymes A/S | Compositions comprising polypeptides having alkaline phosphatase activity |
EP4461796A1 (en) | 2023-05-10 | 2024-11-13 | Novozymes A/S | Detergent composition comprising laccase |
EP4461795A1 (en) | 2023-05-10 | 2024-11-13 | Novozymes A/S | Detergent composition comprising laccase |
WO2025002934A1 (en) | 2023-06-28 | 2025-01-02 | Novozymes A/S | Detergent composition comprising lipases |
WO2025011933A1 (en) | 2023-07-07 | 2025-01-16 | Novozymes A/S | Washing method for removing proteinaceous stains |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4707446A (en) * | 1983-05-24 | 1987-11-17 | Cetus Corporation | Stable haloperoxidase method |
AU642980B2 (en) * | 1990-03-21 | 1993-11-04 | Quest International B.V. | Ultilization of enzymes |
GB9015910D0 (en) * | 1990-07-19 | 1990-09-05 | Univ Bruxelles | Novel use |
JP3399549B2 (en) * | 1990-11-16 | 2003-04-21 | サントリー株式会社 | Microbial peroxidase gene |
KR930703012A (en) * | 1991-02-21 | 1993-11-29 | 잭슨 티. 스티븐스 쥬니어 | Methods and compositions thereof for the control of polara and for the treatment of infections |
US5262151A (en) * | 1991-11-25 | 1993-11-16 | Montgomery Robert E | Stabilized enzymatic antimicrobial compositions |
-
1994
- 1994-06-24 NL NL9401048A patent/NL9401048A/en not_active Application Discontinuation
-
1995
- 1995-03-31 AU AU22154/95A patent/AU2215495A/en not_active Abandoned
- 1995-03-31 BR BR9507226A patent/BR9507226A/en not_active Application Discontinuation
- 1995-03-31 CN CN95192407A patent/CN1146782A/en active Pending
- 1995-03-31 SK SK1230-96A patent/SK123096A3/en unknown
- 1995-03-31 CZ CZ19962850A patent/CZ288041B6/en not_active IP Right Cessation
- 1995-03-31 JP JP7525418A patent/JPH09511396A/en active Pending
- 1995-03-31 WO PCT/EP1995/001229 patent/WO1995027046A2/en active IP Right Grant
- 1995-03-31 CA CA002182966A patent/CA2182966A1/en not_active Abandoned
- 1995-03-31 HU HU9602673A patent/HUT74967A/en unknown
- 1995-03-31 EP EP95915183A patent/EP0753055A1/en not_active Withdrawn
- 1995-03-31 PL PL95316571A patent/PL181389B1/en unknown
- 1995-03-31 PL PL95341279A patent/PL181397B1/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1327772C (en) * | 2001-12-04 | 2007-07-25 | 诺和酶股份有限公司 | Methods for killing spores |
CN101827527A (en) * | 2007-10-23 | 2010-09-08 | 诺维信公司 | Methods for killing spores and disinfecting or sterilizing devices |
CN105120681A (en) * | 2013-05-08 | 2015-12-02 | 诺维信公司 | Animal feed enzymes |
Also Published As
Publication number | Publication date |
---|---|
BR9507226A (en) | 1997-09-09 |
PL316571A1 (en) | 1997-01-20 |
CA2182966A1 (en) | 1995-10-12 |
PL181397B1 (en) | 2001-07-31 |
WO1995027046A2 (en) | 1995-10-12 |
SK123096A3 (en) | 1997-06-04 |
AU2215495A (en) | 1995-10-23 |
EP0753055A1 (en) | 1997-01-15 |
JPH09511396A (en) | 1997-11-18 |
CZ288041B6 (en) | 2001-04-11 |
HU9602673D0 (en) | 1996-11-28 |
NL9401048A (en) | 1995-11-01 |
WO1995027046A3 (en) | 1995-11-30 |
CZ285096A3 (en) | 1997-10-15 |
PL181389B1 (en) | 2001-07-31 |
HUT74967A (en) | 1997-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1146782A (en) | Enzymatic antimicrobial compositions | |
CN102858968B (en) | Variants of a lysozyme and polynucleotides encoding same | |
Michel Jr et al. | Role of manganese peroxidases and lignin peroxidases of Phanerochaete chrysosporium in the decolorization of kraft bleach plant effluent | |
AU721122B2 (en) | Haloperoxidases from curvularia verruculosa and nucleic acids encoding same | |
EP0290568B1 (en) | Enzymatic detergent additive | |
CN1257917A (en) | Amylase | |
KR101739770B1 (en) | Novel fungal protease and use thereof | |
JP4137526B2 (en) | Keratinase and production method thereof | |
JP3327469B2 (en) | Methods for biological inactivation of nucleic acids | |
JP2002506638A (en) | Haloperoxidase with modified pH characteristics | |
US6372465B2 (en) | Haloperoxidases with altered pH profiles | |
DE10328887B4 (en) | Alkaline protease | |
CN1891820B (en) | Cholesterol oxidase stable in the presence of surfactant | |
EP0852260A1 (en) | Oxidase, microorganisms producing the same and use of the same | |
CN107002049A (en) | Polypeptide with N acerylglucosamine oxidase actives | |
JPH09275977A (en) | New lipase and detergent composition | |
WO2000050582A1 (en) | Novel enzyme having decoloring activity and method for decoloring dyes by using the same | |
EP1847599A1 (en) | Polypeptides with perhydrolase activity | |
Wever et al. | Structure and physiological function of vanadium chloroperoxidase | |
BE1009844A3 (en) | Process for harvesting protein. | |
JP3823310B2 (en) | Novel alkaline lipase and process for producing the same | |
JPH10174583A (en) | Oxidation enzyme, its production and use | |
MXPA00008969A (en) | HALOPEROXIDASES WITH ALTERED pH PROFILES | |
JP2002017347A (en) | Method for increasing production of lignin peroxidase and method for utilizing the same | |
Jackson | Microbial response to oxidising biocides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |